Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure

Heart Failure Reviews

Volumn 21, Issue 1, 2016, Pages 95-102

  Greene, Stephen J ^a   Sabbah, Hani N ^b   Butler, Javed ^c   Voors, Adriaan A ^d   Albrecht Küpper, Barbara E ^e   Düngen, Hans Dirk ^f   Dinh, Wilfried ^e,g   Gheorghiade, Mihai ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e BAYER PHARMA AG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g HELIOS KLINIKUM WUPPERTAL   (Germany)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adenosine; Adenosine A1 receptor; Heart failure; Mitochondria; Partial agonist; Therapy

Indexed keywords

ADENOSINE A1 RECEPTOR; CAPADENOSON; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3; ADENOSINE A1 RECEPTOR AGONIST; CARDIOVASCULAR AGENT;

ARTICLE; CELL FUNCTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART OUTPUT; HEART PROTECTION; HUMAN; MITOCHONDRIAL FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PROTEIN EXPRESSION; PROTEIN FUNCTION; HEART STROKE VOLUME; METABOLISM; PARTIAL AGONISM; PHYSIOLOGY;

ADENOSINE A1 RECEPTOR AGONISTS; CARDIOVASCULAR AGENTS; DRUG PARTIAL AGONISM; HEART FAILURE; HUMANS; RECEPTOR, ADENOSINE A1; STROKE VOLUME;

EID: 84954394837     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-015-9522-7     Document Type: Article

References (51)

1. Butler J, Fonarow GC, Gheorghiade M (2013) Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA 310:2035–2036
2. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885
3. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004
4. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J (2013) The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 10:85–97
5. Vaduganathan M, Butler J, Pitt B, Gheorghiade M (2015) Contemporary drug development in heart failure: call for hemodynamically neutral therapies. Circ Heart Fail 8:826–831
6. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309:1125–1135
7. Bayeva M, Sawicki KT, Butler J, Gheorghiade M, Ardehali H (2014) Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail 7:680–691
8. Bayeva M, Gheorghiade M, Ardehali H (2013) Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 61:599–610
9. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M (2014) Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J Am Coll Cardiol 63:2188–2198
10. Greene SJ, Gheorghiade M, Borlaug BA, Pieske B, Vaduganathan M, Burnett JC Jr, Roessig L, Stasch JP, Solomon SD, Paulus WJ, Butler J (2013) The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc 2:e000536
11. Wilcox JE, Fonarow GC, Ardehali H, Bonow RO, Butler J, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, Diez J, Gheorghiade M (2015) “Targeting the Heart” in heart failure: myocardial recovery in heart failure with reduced ejection fraction. JACC Heart Fail 3:661–669
12. Sabbah HN, Gupta RC, Kohli S, Wang M, Rastogi S, Zhang K, Zimmermann K, Diedrichs N, Albrecht-Kupper BE (2013) Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail 6:563–571
13. Linden J (2005) Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67:1385–1387
14. Brodde OE, Michel MC (1999) Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51:651–690
15. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527–552
16. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461–1468
17. Akbar M, Okajima F, Tomura H, Shimegi S, Kondo Y (1994) A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Mol Pharmacol 45:1036–1042
18. Wang D, Belardinelli L (1994) Mechanism of the negative inotropic effect of adenosine in guinea pig atrial myocytes. Am J Physiol 267:H2420–2429
19. Yuan K, Cao C, Han JH, Kim SZ, Kim SH (2005) Adenosine-stimulated atrial natriuretic peptide release through A1 receptor subtype. Hypertension 46:1381–1387
20. Schutte F, Burgdorf C, Richardt G, Kurz T (2006) Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Can J Physiol Pharmacol 84:573–577
21. Xiang F, Huang YS, Zhang DX, Chu ZG, Zhang JP, Zhang Q (2010) Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes. Clin Exp Pharmacol Physiol 37:343–349
22. Martynyuk AE, Kane KA, Cobbe SM, Rankin AC (1996) Nitric oxide mediates the anti-adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells. Pflugers Arch 431:452–457
23. Kirsch GE, Codina J, Birnbaumer L, Brown AM (1990) Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 259:H820–826
24. Albrecht-Kupper BE, Leineweber K, Nell PG (2012) Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal 8:91–99
25. Vallon V, Muhlbauer B, Osswald H (2006) Adenosine and kidney function. Physiol Rev 86:901–940
26. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC (2007) The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50:1551–1560
27. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S (2007) The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 13:609–617
28. Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363:1419–1428
29. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller AB, Pina IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, Delucca P, Salerno CM, Mansoor GA, Dittrich H, O’Connor CM, Massie BM (2012) The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf 35:233–244
30. Dunwiddie TV, Worth T (1982) Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther 220:70–76
31. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L (2013) Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15:1173–1184
32. Francis GS, Bartos JA, Adatya S (2014) Inotropes. J Am Coll Cardiol 63:2069–2078
33. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN (2000) Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol 32:2361–2367
34. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN (2007) Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 42:150–158
35. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A (1999) Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85:357–363
36. Siwik DA, Colucci WS (2004) Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 9:43–51
37. Laskowski KR, Russell RR 3rd (2008) Uncoupling proteins in heart failure. Curr Heart Fail Rep 5:75–79
38. Bugger H, Guzman C, Zechner C, Palmeri M, Russell KS, Russell RR 3rd (2011) Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation. Cancer Chemother Pharmacol 67:1381–1388
39. Sabbah HN (2000) Apoptotic cell death in heart failure. Cardiovasc Res 45:704–712
40. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H (2001) Metabolic gene expression in fetal and failing human heart. Circulation 104:2923–2931
41. Sack MN, Kelly DP (1998) The energy substrate switch during development of heart failure: gene regulatory mechanisms (review). Int J Mol Med 1:17–24
42. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116:258–267
43. Staehr PM, Dhalla AK, Zack J, Wang X, Ho YL, Bingham J, Belardinelli L (2013) Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol 53:385–392
44. Mann DL, Barger PM, Burkhoff D (2012) Myocardial recovery and the failing heart: Myth, magic, or molecular target? J Am Coll Cardiol 60:2465–2472
45. Urmaliya VB, Pouton CW, Devine SM, Haynes JM, Warfe L, Scammells PJ, White PJ (2010) A novel highly selective adenosine A1 receptor agonist VCP28 reduces ischemia injury in a cardiac cell line and ischemia-reperfusion injury in isolated rat hearts at concentrations that do not affect heart rate. J Cardiovasc Pharmacol 56:282–292
46. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34:1711–1720
47. Shneyvays V, Mamedova LK, Leshem D, Korkus A, Shainberg A (2002) Insights into the cardioprotective function of adenosine A(1) and A(3) receptors. Exp Clin Cardiol 7:138–145
48. Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T (1993) Ischemic preconditioning increases adenosine release and 5′-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage. Circulation 87:208–215
49. Tendera M, Gaszewska-Zurek E, Parma Z, Ponikowski P, Jankowska E, Kawecka-Jaszcz K, Czarnecka D, Krzeminska-Pakula M, Bednarkiewicz Z, Sosnowski M, Ochan Kilama M, Agrawal R (2012) The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol 101:585–591
50. Bott-Flugel L, Bernshausen A, Schneider H, Luppa P, Zimmermann K, Albrecht-Kupper B, Kast R, Laugwitz KL, Ehmke H, Knorr A, Seyfarth M (2011) Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism. PLoS ONE 6:e18048
51. Greene SJ, Gheorghiade M (2014) Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. J Am Coll Cardiol 64:1599–1601